JMIR Neurotechnology Invites Submissions on Brain-Computer Interfaces (BCIs)

JMIR Publications is pleased to announce a new theme issue in JMIR Neurotechnology exploring brain-computer interfaces (BCIs) that represent the transformative convergence of neuroscience, engineering, and technology.

Weizmann Institute Optogeneticists Use Mosquito Rhodopsins to Boost Brain Research

The Weizmann Institute’s Prof. Ofer Yizhar and colleagues used mosquito rhodopsins to create an optogenetics tool that is more precise, selective, and controllable than current techniques. In addition to increasing our understanding of the brain and advancing the field of optogenetics, the technology could lead to improved therapies for neurological and psychiatric conditions.

Marine organisms use previously undiscovered receptors to detect, respond to light

Single-celled organisms in the open ocean use a diverse array of genetic tools to detect light, even in tiny amounts, and respond. The discovery of these new genetic “light switches” could also aid in the field of optogenetics, in which a cell’s function can be controlled with exposure to light.

Controlling Cardiac Waves with Light to Better Understand Abnormally Rapid Heart Rhythms

Over 300,000 people die each year in the U.S. due to sudden cardiac death. In many cases, sudden cardiac death is caused by abnormally rapid heart rhythms called tachycardias, which means the heart cannot pump adequate blood to the body. In Chaos, researchers use mice to study tachycardias and find there are intrinsic mechanisms that exist in heart tissue that they hypothesize lead to the self-termination of rapid cardiac rhythm.

Scientists use gene therapy and a novel light-sensing protein to restore vision in mice

A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of MCO1. The company is planning a U.S. clinical trial for later this year.